Travere Therapeutics, Inc. (NASDAQ:TVTX) Cantor Global Healthcare Conference 2025 September 4, 2025 2:45 PM EDT
Company Participants
Eric Dube – President, CEO & Director
Peter Heerma – Chief Commercial Officer
Conference Call Participants
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Presentation
Prakhar Agrawal
Senior Biotech Analyst
All right. Hello, everyone. My name is Prakhar Agrawal. I’m a biotech analyst at Cantor. Welcome to day 2 of the Cantor’s Global Healthcare Conference. For the next session, we are very excited to host the team of Travere Therapeutics. Representing Travere, we have Eric Dube, President and CEO; and Peter Heerma, Chief Commercial Officer. Gentlemen, thank you for coming.
Eric Dube
President, CEO & Director
Thanks for hosting us.
Peter Heerma
Chief Commercial Officer
My pleasure.
Question-and-Answer Session
Prakhar Agrawal
Cantor Fitzgerald & Co., Research Division
So obviously, a lot going on at Travere right now. We’ll go into the specifics. But maybe just to level set expectations, why don’t you start with an overview of the key priorities right now for the company?
Eric Dube
President, CEO & Director
Sure. So this is indeed an exciting year for Travere and the role that we look to play within the rare kidney and broader rare disease space. Our #1 priority for this year is to continue the success of the launch of FILSPARI in IgA nephropathy. And we’ve been very pleased with the performance for the first half of the year. And we’ve got some very exciting updates to continue that success in the back half of this year, including the recent modification of the liver monitoring REMS and the removal of the pregnancy testing REMS, which makes it that much simpler for patients to access.
The second priority is the ongoing work with FDA for the potential approval in FSGS. This would be
#Travere #Therapeutics #TVTX #Presents #Cantor #Global #Healthcare #Conference #Tra